IMR Press / EJGO / Special Issues / 1631064256707

Triple Negative Breast Cancer

Section: Breast Cancer
Submission deadline: 31 March 2022
Special Issue Editors
Patrick Neven, MD
Department of Gynecological Oncology, Multidisciplinary Breast Center, Leuven University Hospitals, Herestraat 49, Leuven, Belgium
Interests: Breast Cancer
Special Issue Information

Dear Colleagues,
Triple negative breast cancer (TNBC) is a heterogeneous disease comprising different orphan breast cancers and defined simply by the absence of ER, PR and HER-2. Approximately 15%-20% of breast cancers exhibit this phenotype, which is characterised by distinct risk factors and molecular features, and a particular clinical presentation and outcome. These features are discussed in the current review. The risk of developing TNBC varies with age, race, genetics, and reproductive factors such as parity and breastfeeding patterns. Loco-regional treatment is often performed after upfront systemic treatment in order to increase breast conservation rates. Similar to other invasive breast cancer subtypes, this involves surgery with or without adjuvant radiotherapy. Some TNBC are very chemo-sensitive and the majority of patients will never relapse. A high density of tumor infiltrating lymphocytes and specific histological subgroups of TNBC can indicate a good prognosis, even in the absence of chemotherapy. Distinct molecular subgroups within TNBC such as the luminal androgen receptor positive subtype have also been defined. 
When metastatic relapse does occur in TNBC cases, it is usually within 3 years of surgery and patient survival following relapse is shorter compared to other breast cancer subtypes. Some new treatment options have proven effective, including the AB-drug conjugate against TROP2, PARP inhibitors in cases of homologous recombination deficiency, and immune checkpoint blockade if there is PD-L1 expression. However, successful treatments remain rare and responses often lack durability. Novel drug targets, new biomarkers and further molecular and biological investigations of TNBC are needed to improve care for breast cancer patients presenting with this subtype. 
This special issue of EJGO on the management of early- and late-stage TNBC serves to update the reader on this important topic.

Prof. Patrick Neven

Guest Editor

Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 1500 USD. Submitted manuscripts should be well formatted in good English.

Back to top